BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 27578074)

  • 41. Chronic pruritus: targets, mechanisms and future therapies.
    Pogatzki-Zahn E; Marziniak M; Schneider G; Luger TA; Ständer S
    Drug News Perspect; 2008 Dec; 21(10):541-51. PubMed ID: 19221635
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Opioid-induced pruritus: an update.
    Reich A; Szepietowski JC
    Clin Exp Dermatol; 2010 Jan; 35(1):2-6. PubMed ID: 19663845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic potential of biologics in prurigo nodularis.
    Müller S; Bieber T; Ständer S
    Expert Opin Biol Ther; 2022 Jan; 22(1):47-58. PubMed ID: 34289753
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antipruritic vs. Antitumour Action of Aprepitant: A Question of Dose.
    Muñoz M; Parrilla J; Rosso M; Coveñas R
    Acta Derm Venereol; 2019 May; 99(6):620-621. PubMed ID: 30734049
    [No Abstract]   [Full Text] [Related]  

  • 45. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review.
    Phan NQ; Bernhard JD; Luger TA; Ständer S
    J Am Acad Dermatol; 2010 Oct; 63(4):680-8. PubMed ID: 20462660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Itch Management: Topical Agents.
    Metz M; Staubach P
    Curr Probl Dermatol; 2016; 50():40-5. PubMed ID: 27578070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU).
    Tsianakas A; Zeidler C; Riepe C; Borowski M; Forner C; Gerss J; Metz M; Staubach P; Raap U; Kaatz M; Urban M; Luger TA; Ständer S
    Acta Derm Venereol; 2019 Apr; 99(4):379-385. PubMed ID: 30653242
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Uremic pruritus: an unresolved challenge].
    Aucella F; Gesuete A
    G Ital Nefrol; 2009; 26(5):585-99. PubMed ID: 19802804
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Aprepitant for refractory cutaneous T-cell lymphoma-associated pruritus: 4 cases and a review of the literature.
    Song JS; Tawa M; Chau NG; Kupper TS; LeBoeuf NR
    BMC Cancer; 2017 Mar; 17(1):200. PubMed ID: 28302100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What's New in Cutaneous T-Cell Lymphoma-Associated Pruritus.
    Biazus Soares G; Guitart J; Yosipovitch G
    Am J Clin Dermatol; 2024 Jan; 25(1):67-77. PubMed ID: 37971624
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnosis and Management of Neuropathic Itch.
    Rosen JD; Fostini AC; Yosipovitch G
    Dermatol Clin; 2018 Jul; 36(3):213-224. PubMed ID: 29929594
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Itch Management in the Elderly.
    Leslie TA
    Curr Probl Dermatol; 2016; 50():192-201. PubMed ID: 27578088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current and emerging systemic treatments targeting the neural system for chronic pruritus.
    Golpanian RS; Yosipovitch G
    Expert Opin Pharmacother; 2020 Sep; 21(13):1629-1636. PubMed ID: 32515664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Treatment of chronic itch in systemic disease. Current standards].
    Mettang T; Ständer S; Kremer AE
    Internist (Berl); 2015 Dec; 56(12):1369-78. PubMed ID: 26585238
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Targeted treatment of pruritus: a look into the future.
    Tey HL; Yosipovitch G
    Br J Dermatol; 2011 Jul; 165(1):5-17. PubMed ID: 21219293
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NK-1 Antagonists and Itch.
    Ständer S; Luger TA
    Handb Exp Pharmacol; 2015; 226():237-55. PubMed ID: 25861784
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic hemicorporal prurigo related to a posttraumatic Brown-Séquard syndrome.
    Thielen AM; Vokatch N; Borradori L
    Dermatology; 2008; 217(1):45-7. PubMed ID: 18367840
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant.
    Ohanyan T; Schoepke N; Eirefelt S; Hoey G; Koopmann W; Hawro T; Maurer M; Metz M
    Acta Derm Venereol; 2018 Jan; 98(1):26-31. PubMed ID: 28853492
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Uremic pruritus.
    Mettang T; Kremer AE
    Kidney Int; 2015 Apr; 87(4):685-91. PubMed ID: 24402092
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug-Induced Itch Management.
    Ebata T
    Curr Probl Dermatol; 2016; 50():155-63. PubMed ID: 27578085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.